Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prasco Laboratories and Shire enter an agreement for the distribution of the authorized generic version of Carbatrol (Carbamazepine) Extended-Release Capsules in 100 mg, 200 mg and 300 mg strengths in the US.
Subscribe to our email newsletter
Carbamazepine Extended-Release Capsules are therapeutically equivalent and substitutable for the brand Carbatrol.
Carbatrol is used to treat certain types of seizures (partial, tonic-clonic, mixed) and certain types of nerve pain (trigeminal and glossopharyngeal neuralgia).
The product will be distributed in the US under the Prasco label.
Prasco CEO Christopher H Arington said Carbamazepine Extended-Release Capsules will provide patients with a therapeutically equivalent product to the brand as a Prasco Authorized Generic.
The financial terms of the agreement, however, have not been revealed.